<div class="container">

<table style="width: 100%;"><tr>
<td>power.RatioF</td>
<td style="text-align: right;">R Documentation</td>
</tr></table>
<h2>
Power for equivalence of the ratio of two means with normality on original scale
</h2>

<h3>Description</h3>

<p>Calculates the power of the test of equivalence of the ratio of two means 
with normality on original scale.<br> 
This test is based on Fieller’s confidence (‘fiducial’) interval and Sasabuchi’s 
test (a TOST procedure as well).
</p>


<h3>Usage</h3>

<pre><code class="language-R">power.RatioF(alpha = 0.025, theta1 = 0.8, theta2, theta0 = 0.95,
             CV, CVb, n, design = "2x2", setseed=TRUE)
</code></pre>


<h3>Arguments</h3>

<table>
<tr style="vertical-align: top;">
<td><code>alpha</code></td>
<td>

<p>Type I error probability, aka significance level.<br>
Defaults here to 0.025 because this function is intended for studies
with clinical endpoints. 
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>theta1</code></td>
<td>

<p>Lower bioequivalence limit. Typically 0.8 (default).
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>theta2</code></td>
<td>

<p>Upper bioequivalence limit. Typically 1.25.<br>
Is set to <code>1/theta1</code> if missing.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>theta0</code></td>
<td>

<p>‘True’ or assumed T/R ratio. Typically set to 0.95 for planning.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>CV</code></td>
<td>

<p>Coefficient of variation as ratio. In case of <code>design="parallel"</code> this is
the CV of the total variability, in case of <code>design="2x2"</code> the 
intra-subject CV (CVw in the reference).
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>CVb</code></td>
<td>

<p>CV of the between-subject variability. Only necessary for <code>design="2x2"</code>.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>n</code></td>
<td>

<p>Number of subjects to be planned.<br><code>n</code> is for both designs implemented the <b>total</b> number of subjects.<br></p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>design</code></td>
<td>

<p>A character string describing the study design.<br><code>design="parallel"</code> or <code>design="2x2"</code> allowed for a two-parallel 
group design or a classical TR|RT crossover design.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>setseed</code></td>
<td>

<p>If set to <code>TRUE</code> the dependence of the power from the state of the random number
generator is avoided. With <code>setseed = FALSE</code> you may see the dependence
from the state of the random number generator.
</p>
</td>
</tr>
</table>
<h3>Details</h3>

<p>The power is calculated exact using the bivariate non-central <em>t</em>-distribution
via function <code>pmvt</code> of the package <code>mvtnorm</code>.<br>
Due to the calculation method of the used package mvtnorm – randomized 
Quasi-Monte-Carlo – these probabilities are dependent from the state of the 
random number generator within the precision of the power. 
See argument <code>setseed</code>.
</p>


<h3>Value</h3>

<p>Value of power according to the input.
</p>


<h3>Note</h3>

<p>This function is intended for studies with clinical endpoints where the 95% confidence intervals are usually used for equivalence testing.<br>
Therefore, alpha defaults here to 0.025 (see EMEA 2000).<br><br>
The formulas given in the references rely on the assumption of equal variances
in the two treatment groups for the parallel group design or on assuming equal 
within-subject and between-subject variabilities for the 2×2 crossover design.
</p>


<h3>Author(s)</h3>

<p>D. Labes
</p>


<h3>References</h3>

<p>Fieller EC. <em>Some Problems in Interval Estimation.</em> J Royal Stat Soc B. 1954;16(2):175–85. <a href="https://doi.org/10.1111/j.2517-6161.1954.tb00159.x">doi:10.1111/j.2517-6161.1954.tb00159.x</a>
</p>
<p>Sasabuchi S. <em>A test of a multivariate normal mean with composite hypotheses determined by linear inequalities.</em> Biometrika. 1980;67(2):429–39. <a href="https://doi.org/10.1093/biomet/67.2.429">doi:10.1093/biomet/67.2.429</a>
</p>
<p>Hauschke D, Kieser M, Diletti E, Burke M. <em>Sample size determination for proving equivalence based on the ratio of two means for normally distributed data.</em> Stat Med. 1999;18(1):93–105.
</p>
<p>Hauschke D, Steinijans V, Pigeot I. <em>Bioequivalence Studies in Drug Development.</em> Chichester: Wiley; 2007. Chapter 10.
</p>
<p>European Agency for the Evaluation of Medicinal Products, CPMP. <em>Points to Consider on Switching between Superiority and Non-Inferiority.</em> London, 27 July 2000. <a href="https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-switching-between-superiority-and-non-inferiority_en.pdf">CPMP/EWP/482/99</a>
</p>


<h3>See Also</h3>

<p><code>sampleN.RatioF</code>
</p>


<h3>Examples</h3>

<pre><code class="language-R"># power for alpha=0.025, ratio0=0.95, theta1=0.8, theta2=1/theta1=1.25
# within-subject CV=0.2, between-subject CV=0.4 
# 2x2 crossover study, n=24
# using all the defaults:
power.RatioF(CV = 0.2, CVb = 0.4, n = 24)
# gives [1] 0.7315357
</code></pre>


</div>